Steffen Thiel

Professor, Professor MSO


Personal information

Born                   4 May 1961

Citizenship        Danish

Address             Department of Biomedicine, BartholinsAllé 6, Building1242, 8000 Aarhus C, DK



1991                  PhD in Biochemistry

1987                  Msc in Experimental Biology



2010-present   Professor, Department of Biomedicine, Aarhus University, DK

1994-2010        Associate professor, Department ofMedical Microbiology and Immunology,                            Aarhus University

1996-1997        Visiting scientist, UCSD Cancer Centre, Glycobiology Programme, University                            of California, USA

1994-1996        Benzon Fund Stipend, Aarhus University,DK

1991-1994        Assistant professor, Department of Medical Microbiology and Immunology,                            Aarhus University

1988-1989        Visiting scientist, MRC Immunochemistry Unit, Department of Biochemistry,                            OxfordUniversity, UK

1987-1990        Research assistant, Department ofMedical Microbiology, University of                                    Odense, DK


Honours and Memberships

Recipient of the Hanstedgaard Fund Award, January 2013

Member of Scandinavian Society of Immunology and International Union of Immunological societies. Member of American Association of Immunologists.



H-index: 63(WoS, January 2017) based on 258 publications in peer-reviewed journals,including Nature, New England Journal of Medicine, Immunity, J. of Experimental Medicine, J. Clinical Investigation, EMBO Journal, PNAS and Lancet. Five chapters in scientific books.


Steffen Thiel teaches immunology for medical and natural science students at Aarhus University,and at PhD courses at Eötvös Loránd University in Budapest, Aarhus University and the University of Copenhagen.



SteffenThiel has during the last 25 years acted as supervisor for a number of science and medical students at master and PhD level.



Board member of The Danish Council for Independent Research (Medical Sciences) until 2016.

Examiner of doctoral dissertations at University of Oxford, University of Reykjavik, National University of Singapore, Aarhus University, University of Copenhagen and University of South Denmark

Reviewer of applications from non-Danish scientific funding bodies, including  Biotechnologyand Biological Sciences Research Council, UK, and Cancer Research Fund, UK and NationalScience Centre, Poland

He has served as President of the Danish Society for Immunology and board member of The Scandinavian Society for Immunology and is current board member of the European Complement Network. Former member ofeditorial board of Immunobiology and current Associate Editor of ScandinavianJournal of Immunology

Deputy Head of the Institute of Medical Microbiology and Immunology 1998-2009. Member of the “TheDepartment Forum”, Department of Biomedicine, Aarhus University and of the “Working Environment Committee”, Aarhus University and of “The Research Committee” at Department of Biomedicine, Aarhus University

Reviewer of applications for positions as Assistant professor, Associate professor and Professor at University of Copenhagen,University of Southern Denmark and Aarhus University

Actively participating as chairman and with abstractsand lectures at a number of international meetings and conferences since 1986,e.g. invited to lecture at Annual meeting of Irish Society for Immunology,Dublin, 2016 and at 2nd ALTANT Conference: Innate host defence and infections,Utrect, 2016 and at 15th European Meeting on Complement in Human Disease, Upsala,2015.

President of "Scandinavian Society forImmunology, 35th annual meeting and the 21th summer school", Aarhus, June2004. Co-Organizer of the conferences "Scandinavian Society forImmunology, XXIVth annual meeting and IX summer school", Aarhus, 1993 and“41st Scandinavian Society For Immunology Meeting”, Copenhagen,2013. Organizer ofDanish Immunological Society Annual Meetings.


Founder of the biotech companies NatImmune A/S (founded 2000, and board member and member of SAB) and Helion A/S (boardmember, founded 2008). Both companies established to develop proteintherapeutics within oncology and infectious diseases. Granted five patents.